Classification of protein aggregates

Journal of Pharmaceutical Sciences

Volumn 101, Issue 2, 2012, Pages 493-498

  Narhi, Linda O ^a   Schmit, Jeremy ^b   Bechtold Peters, Karoline ^c   Sharma, Deepak ^d  

^a AMGEN INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d Brightwell Technologies Inc   (Canada)

Author keywords

Amyloid; Dissociation; Modification; Morphology; Oligomers; Particle size; Protein aggregation; Protein structure; Reversibility; Stability

Indexed keywords

OLIGOMER; PROTEIN;

CLASSIFICATION; DISSOCIATION; EQUILIBRIUM CONSTANT; HYDROPHOBICITY; MOLECULAR WEIGHT; MORPHOLOGY; NOMENCLATURE; NOTE; PARTICLE SIZE; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; PROTEIN CONFORMATION; PROTEIN CROSS LINKING; PROTEIN FOLDING; PROTEIN MODIFICATION; PROTEIN STABILITY; PROTEIN STRUCTURE; THERMODYNAMICS;

EID: 84455208309     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22790     Document Type: Note

References (23)

1. Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJ, Middaugh CR, Winter G, Fan YX, Kirshner S, Verthelyi D, Kozlowski S, Clouse KA, Swann PG, Rosenberg A, Cherney B. 2009. Overlooking Subvisible Particles in Therapeutic Protein Products: Gaps That May Compromise Product Quality. J Pharm Sci 98:1201-1205.
2. Mahler HC, Friess W, Grauschopf U, Kiese S. 2009. Protein Aggregation: Pathways, Induction Factors and Analysis. J Pharm Sci 98:2909-2934.
3. Singh SK, Afonina N, Awwad M, Bechtold-Peters K, Blue JT, Chou D, Cromwell M, Krause HJ, Mahler HC, Meyer BK, Narhi L, Nesta DP, Spitznagel T. 2010. An Industry Perspective on the Monitoring of Subvisible Particles as a Quality Attribute for Protein Therapeutics. J Pharm Sci 99:3302-3321.
4. Narhi LO, Jiang Y, Cao S, Benedek K, Shnek D. 2009. A Critical Review of Analytical Methods for Subvisible and Visible Particles. Curr Pharm Biotech 10:373-381.
5. Wang W, Roberts CJ, Eds. 2010. Aggregation of therapeutic proteins. Hoboken, New Jersey: Wiley.
6. Sharma VK, Kalonia, DS. 2010. Experimental detection and characterization of protein aggregates. In Aggregation of therapeutic proteins; Wang W, Roberts CJ, Eds. Hoboken, New Jersey: Wiley.
7. Jenkins AD, Kratochvil P, Suter UW. 1996. Glossary of basic terms in polymer science. Pure Appl Chem 68:2287-2311 (IUPAC, available at. 08/04/2011).
8. Goda S, Takano K, Yamagata Y, Nagata R, Akutsu H, Maki S, Namba K, Yutani K. 2000. Protein Sci 9:369-375.
9. Vicéns M. 2009. Pharmaceutical Formulation & Quality. December/January 2009.
10. Bitan G, Fradinger EA, Spring SM, Teplow DB. 2005. Neurotoxic protein oligomers - what you see is not always what you get. Amyloid 12:88-95.
11. Moore JMR, Patapoff TW, Cromwell MEE. 1999. Kinetics and thermodynamics of dimer formation and dissociation for a recombinant humanized monoclonal antibody to vascular endothelial growth factor. Biochemistry 38:13960-13967.
12. Kanai S, Liu J, Patapoff TW, Shire SJ. 2008. Reversible self-association of a concentrated monoclonal antibody solution mediated by Fab-Fab interaction that impacts solution viscosity. J Pharm Sci 97:42419-4227.
13. Kiese S, Pappenberger A, Friess W, Mahler HC. 2008. Shaken, not stirred: Mechanical stress testing of an IgG1 antibody. J Pharm Sci 97:4347-4366.
14. Joubert M, Luo Q, Nashed-Samuel Y, Wypych J, Narhi LO. 2011. Classification and Characterization of Therapeutic Antibodies. J Biol Chem 286:25118-25133.
15. Luo Q, Joubert MK, Ketchum, R, Stevenson, R, Narhi, LO, Wypych, J. 2011. Chemical Modifications in Therapeutic Protein Aggregates Generated Under Different Stress Conditions. J Biol Chem 286:25134-25144.
16. Fradkin AH, Carpenter JF, Randolph TW. 2009. Immunogenicity of Aggregates of Recombinant Human Growth Hormone in Mouse Models. J Pharm Sci 98:3247-3264.
17. Bechtold-Peters K. 2010. Protein immobilization by crystallization and precipitation: An alternative to lyophilization. In Current trends in monoclonal antibody development and manufacturing; Shire S, Gombotz W, Bechtold-Peters K, Andva J, Eds. New York: Springer.
18. Tyagi A, Randolph TA, Dong A, Maloney KM, Hitscherich CJ, Carpenter JF. 2009. IgG Particle Formation during Filling Pump Operation: A Case Study of Heterogeneous Nucleation on Stainless Steel Nanoparticles. J Pharm Sci 98:94-104.
19. Chi EY, Weickmann J, Carpenter JF, Manning MC, Randolph TW. 2005. Heterogeneous nucleation-controlled particulate formation of recombinant human platelet-activating factor acetylhydrolase in pharmaceutical formulation. J Pharm Sci 94:256-274.
20. Liu W, Swift R, Torraca G, Nashed-Samuel Y, Wen ZQ, Jiang Y, Vance A, Mire-Sluis A, Freund E, Davis J, Narhi LO. 2010. Root Cause Analysis of Tungsten-Induced Protein Aggregation in Pre-filled Syringes PDA Journal of Pharmaceutical Science and Technology. PDA J Pharm Sci Technol 64:11-19.
21. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Kraft GA, Klein WL. 1998. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci 95:6448-6453.
22. Barghorn S, Nimmrich V, Striebinger A, Krantz C, Keller P, Janson B, Bahr M, Schmidt M, Bitner RS, Harlan J, Barlow E, Ebert U, Hillen H. 2005. Globular amyloid beta-peptide(1-42) oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. J Neurochem 95:834-847.
23. Westlind-Danielsson A, Arnerup G. 2001. Spontaneous in vitro formation of supramolecular beta-amyloid structures, "betaamy balls", by beta-amyloid 1-40 peptide. Biochemistry 40:14736-14743.